پازوپانیب (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "پازوپانیب" in Persian language version.

refsWebsite
Global rank Persian rank
1st place
1st place
68th place
179th place
4th place
5th place
719th place
248th place
3,823rd place
1,188th place
3,984th place
1,143rd place
2nd place
2nd place

doi.org

  • Zivi, A; Cerbone, L; Recine, F; Sternberg, CN (September 2012). "Safety and tolerability of pazopanib in the treatment of renal cell carcinoma". Expert Opinion on Drug Safety. 11 (5): 851–859. doi:10.1517/14740338.2012.712108. PMID 22861374.

europa.eu

ema.europa.eu

  • "CHMP Assessment Report: Votrient (pazopanib)" (PDF). European Medicines Agency. Archived from the original (PDF) on 9 اكتبر 2016. Retrieved 8 October 2016. {{cite web}}: Check date values in: |archive-date= (help)
  • "Votrient: EPAR - Product Information" (PDF). European Medicines Agency. Glaxo Group Ltd. 23 January 2014. Archived from the original (PDF) on 4 February 2014. Retrieved 27 January 2014.

medicines.org.uk

medscape.com

reference.medscape.com

nih.gov

dailymed.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov

  • Zivi, A; Cerbone, L; Recine, F; Sternberg, CN (September 2012). "Safety and tolerability of pazopanib in the treatment of renal cell carcinoma". Expert Opinion on Drug Safety. 11 (5): 851–859. doi:10.1517/14740338.2012.712108. PMID 22861374.

tga.gov.au

ebs.tga.gov.au

web.archive.org

  • "CHMP Assessment Report: Votrient (pazopanib)" (PDF). European Medicines Agency. Archived from the original (PDF) on 9 اكتبر 2016. Retrieved 8 October 2016. {{cite web}}: Check date values in: |archive-date= (help)
  • "Votrient: EPAR - Product Information" (PDF). European Medicines Agency. Glaxo Group Ltd. 23 January 2014. Archived from the original (PDF) on 4 February 2014. Retrieved 27 January 2014.